Targeted beta therapy of prostate cancer with 177 Lu-labelled Miltuximab ® antibody against glypican-1 (GPC-1)

ConclusionThese findings demonstrate the potential utility of Miltuximab ® as a PET imaging agent ([89Zr]Zr-DFO-Miltuximab ®) and a beta therapy ([177Lu]Lu-DOTA-Miltuximab ®) in patients with PCa or other GPC-1 expressing tumours.
Source: EJNMMI Research - Category: Radiology Source Type: research